Langerhans Cell Histiocytosis: Understanding Your Pathology Report

Section Editor: David Li MD
June 28, 2026

Langerhans cell histiocytosis (LCH) is a rare disorder in which a specific type of immune cell grows and builds up in tissues where it does not normally belong. These abnormal cells resemble Langerhans cells, immune cells that normally help respond to infection and inflammation. In Langerhans cell histiocytosis, the cells proliferate clonally (non-randomly) and form lesions that can damage surrounding tissue. Although it was once thought to be purely an immune reaction, it is now understood to be a neoplasm (a tumor) driven by genetic changes in cells. Langerhans cell histiocytosis can involve a single organ or body system (most often bone) or several organs at the same time, and the extent of involvement is one of the most important factors affecting symptoms, treatment, and outlook.

This article will help you understand the findings in your pathology report for Langerhans cell histiocytosis, what each term means, and why it matters for your care.

Where does Langerhans cell histiocytosis occur?

The location of Langerhans cell histiocytosis (LCH) depends on whether it affects a single system or multiple systems. In single-system disease, the most commonly involved site is bone, especially the skull, thigh bone (femur), spine, pelvis, ribs, and jaw. Less commonly, single-system disease affects the skin, lymph nodes, or lungs. In multisystem disease, several organs may be involved at once, most often the skin, bone, liver, spleen, and bone marrow, and in advanced cases other organs as well.

What are the symptoms of Langerhans cell histiocytosis?

The symptoms of Langerhans cell histiocytosis (LCH) vary widely depending on how many organs are involved and which ones they are.

Single-system disease most often affects older children or adults. When bone is involved, the usual symptom is localized pain from a destructive lesion, and the area may be tender, swollen, or prone to fracture. Lesions in the skull or jaw may be noticed as a lump or as facial asymmetry. If the disease affects the skull or nearby brain structures, it can damage the pituitary gland and cause diabetes insipidus, a condition that leads to excessive thirst and frequent urination. When single-system disease involves the skin or lymph nodes, it may appear as a localized rash or mass.

Multisystem disease is more common in infants and very young children and tends to be more severe. These patients may have fever, poor appetite, weight loss, and fatigue, often with skin rashes and multiple bone lesions. Involvement of the liver, spleen, or bone marrow can cause these organs to enlarge and can lower the blood counts (cytopenias). These features indicate higher-risk disease and usually call for more intensive treatment.

How common is Langerhans cell histiocytosis?

Langerhans cell histiocytosis (LCH) is rare. In children, it occurs in about 5 cases per million per year, and it is less common in adults, at about 1 to 2 cases per million per year. It affects males slightly more often than females and is reported more frequently in people of European or Hispanic ancestry. Langerhans cell histiocytosis can occur on its own or, rarely, alongside other histiocytic disorders such as Erdheim-Chester disease.

What causes Langerhans cell histiocytosis?

The exact cause of Langerhans cell histiocytosis (LCH) is not fully understood, and the disease is not inherited. Research has shown that it is driven by acquired genetic mutations (changes in the DNA) that affect a signaling pathway inside cells called the MAPK pathway. These mutations cause the immune cells to survive longer than they should and to accumulate in tissues. The most common change involves the BRAF gene (specifically the BRAF V600E mutation), and other cases involve related genes such as MAP2K1. These changes help explain why the disease can behave like both an inflammatory condition and a cancer.

How is the diagnosis made?

The diagnosis of Langerhans cell histiocytosis (LCH) is made by examining a biopsy from an affected site, such as bone, skin, or a lymph node, under the microscope and confirming the identity of the abnormal cells with special tests. Under the microscope, the abnormal cells are medium-sized and have characteristic grooved or folded nuclei, often described as “coffee-bean shaped.” The chromatin inside the nucleus is fine, and the cytoplasm is moderately abundant and lightly pink. The cells are usually found in a mixed inflammatory background that often includes eosinophils, a type of white blood cell commonly seen in this disease, along with other immune cells. In bone lesions, cells resembling osteoclasts (the cells that break down bone) may also be present.

To confirm the diagnosis, the pathologist uses immunohistochemistry, a test that employs special stains to detect proteins produced by cells. The cells of Langerhans cell histiocytosis characteristically produce CD1a and CD207 (also called langerin), as well as S100 protein, and this combination confirms that the cells have a Langerhans cell identity. CD68 and HLA-DR are also commonly positive. A specific stain can detect the BRAF V600E mutation in many cases, which helps guide treatment.

Genetic changes and molecular testing in Langerhans cell histiocytosis

Molecular testing looks for the genetic changes that drive Langerhans cell histiocytosis (LCH) and helps both confirm the diagnosis and guide treatment. These tests are usually performed on the biopsy tissue using methods such as next-generation sequencing, PCR-based mutation testing, or, in some cases, immunohistochemistry designed to detect a specific mutation. Results are usually reported by naming the affected gene and the specific change, such as BRAF V600E or a MAP2K1 mutation, and the report may describe the mutation as present (positive) or not detected (negative). Identifying a mutation in the MAPK pathway is important because it supports the diagnosis and can open the door to targeted treatment, particularly in recurrent or multisystem disease.

How is Langerhans cell histiocytosis staged?

Langerhans cell histiocytosis (LCH) is staged based on the number of organs involved, not on tumor size. Single-system disease involves one organ or system, either at a single site or at several sites, while multisystem disease involves two or more organs or systems. Some organs, particularly the liver, spleen, and bone marrow, are considered risk organs, and their involvement indicates higher-risk disease.

What is the prognosis for Langerhans cell histiocytosis?

The outlook for Langerhans cell histiocytosis (LCH) depends mainly on the extent of disease at diagnosis. Patients with single-system disease have an excellent outlook, with survival rates approaching 100%, and many cases resolve completely with limited treatment. Patients with multisystem disease, especially when risk organs are involved, have a more complicated course but still have a relatively low overall mortality rate with modern therapy. Long-term complications can occur, particularly in patients with pituitary or brain involvement. Certain genetic changes, especially the BRAF V600E mutation, are associated with a higher risk of the disease returning and may influence treatment choices. Your prognosis depends on your own combination of these factors, which your care team can explain in the context of your specific report.

What happens after a diagnosis of Langerhans cell histiocytosis?

After Langerhans cell histiocytosis (LCH) is diagnosed, treatment depends mainly on the extent of involvement. The pathology and genetic findings help guide several decisions:

Local treatment or observation — A single bone lesion is often managed with local approaches, such as biopsy, surgical curettage (scraping out the lesion), or injection of a steroid into the lesion, and some lesions are simply watched closely because they can heal on their own.
Systemic chemotherapy — Multisystem disease or disease involving risk organs is usually treated with medicines that travel throughout the body. In children, the standard first-line treatment is vinblastine combined with a steroid (prednisone), and drugs such as cytarabine or cladribine are also used, particularly in adults and for disease that returns.
Targeted therapy — For disease with a BRAF V600E mutation, BRAF inhibitors (such as vemurafenib or dabrafenib) can rapidly control active disease. For other MAPK pathway mutations, MEK inhibitors (such as cobimetinib or trametinib) may be used.
Treatment of diabetes insipidus — When the pituitary gland is affected, hormone replacement with desmopressin manages excessive thirst and urination, often long-term.

Because Langerhans cell histiocytosis can affect many organs, care is often shared among several specialists, and long-term follow-up is important to monitor for disease recurrence and to manage late effects, especially those involving the pituitary gland and nervous system. Clinical trials of newer therapies may also be an option to discuss. Decisions about treatment are made by the care team together with the patient (or the family), based on the specific findings in the report.

Questions to ask your doctor

Is my disease single-system or multisystem?
Which organs are involved, and are any of them risk organs (liver, spleen, or bone marrow)?
Was molecular testing performed, and was a BRAF V600E or other MAPK mutation found?
Could I benefit from targeted therapy such as a BRAF or MEK inhibitor?
What treatment is recommended for the extent of my disease?
Is the pituitary gland involved, and am I at risk for diabetes insipidus?
What is my prognosis based on my specific findings?
What long-term effects should I watch for, and what follow-up will I need?
What are the chances that the disease will come back after treatment?
Are there clinical trials that I should consider?